New combo therapy for recurrent brain cancer shows promise
NCT ID NCT01743950
First seen Mar 28, 2026 · Last updated Apr 28, 2026 · Updated 2 times
Summary
This study tested a special type of radiation (pulse reduced dose rate) combined with the drug bevacizumab in 49 people with recurrent high-grade gliomas (grade 3 or 4 brain tumors). Participants received radiation over 5.5 weeks along with bevacizumab, followed by continued bevacizumab until the tumor progressed. The goal was to see if this combination could improve overall survival and control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.